POINT-Logo-Colour (1).png
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
May 05, 2022 09:15 ET | POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT-Logo-Colour (1).png
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
April 26, 2022 08:30 ET | POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
POINT-Logo-Colour (1).png
POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting
April 11, 2022 16:30 ET | POINT Biopharma
POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...
Nextnav logo.png
NextNav Showcases APNT Backup to GNSS at European Commission's Joint Research Centre’s Trial
February 01, 2022 13:36 ET | NextNav
SUNNYVALE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NextNav (Nasdaq: NN) today announced that it has recently participated in the European Commission’s Joint Research Centre (JRC) alternative...
NextNav and Satelles Collaborate to Establish an Alternative PNT Testbed in the San Francisco Bay Area
October 05, 2021 09:00 ET | NextNav; Satelles, Inc.
SUNNYVALE, Calif. and RESTON, Va., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NextNav and Satelles, Inc. today announced that they have partnered on an alternative positioning, navigation, and timing (PNT)...
POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor
September 28, 2021 08:00 ET | POINT Biopharma
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic...
POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC
September 23, 2021 08:00 ET | POINT Biopharma
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS,...
Nextnav logo.png
NextNav Demonstrates World’s First GPS-Free PNT Network in Department of Homeland Security Trial
August 16, 2021 09:00 ET | NextNav
SUNNYVALE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- NextNav, the leader in next generation GPS, announced today that it has successfully demonstrated the timing precision and resilience of its...
Screen Shot 2020-12-07 at 3.17.51 PM.png
InvenSense Barometric Sensor First to Achieve NextNav Certified Status
June 17, 2021 09:00 ET | NextNav
SUNNYVALE, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- NextNav, the leader in 3D geolocation, today announced that the ICP-10111 barometric sensor from InvenSense, a TDK group company, is the first to...
Screen Shot 2020-12-07 at 3.17.51 PM.png
3AM Innovations and NextNav improve first responder safety and situational awareness with vertical location
March 31, 2021 09:00 ET | NextNav
SUNNYVALE, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- NextNav, the leader in 3D geolocation, today announced a new partnership with 3AM Innovations to deliver improved situational awareness for...